Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
15 "Carcinoma, non-small cell lung"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Reviews
Current status and future perspectives of liquid biopsy in non-small cell lung cancer
Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
J Pathol Transl Med. 2020;54(3):204-212.   Published online April 15, 2020
DOI: https://doi.org/10.4132/jptm.2020.02.27
  • 5,940 View
  • 252 Download
  • 11 Citations
AbstractAbstract PDF
With advances in target therapy, molecular analysis of tumors is routinely required for treatment decisions in patients with advanced non-small cell lung cancer (NSCLC). Liquid biopsy refers to the sampling and analysis of circulating cell-free tumor DNA (ctDNA) in various body fluids, primarily blood. Because the technique is minimally invasive, liquid biopsies are the future in cancer management. Epidermal growth factor receptor (EGFR) ctDNA tests have been performed in routine clinical practice in advanced NSCLC patients to guide tyrosine kinase inhibitor treatment. In the near future, liquid biopsy will be a crucial prognostic, predictive, and diagnostic method in NSCLC. Here we present the current status and future perspectives of liquid biopsy in NSCLC.

Citations

Citations to this article as recorded by  
  • Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics
    Hyun Hee Koh, Eunhyang Park, Hyun-Soo Kim
    Diagnostics.2022; 12(2): 326.     CrossRef
  • Alveolar Soft Part Sarcoma of the Uterus: Clinicopathological and Molecular Characteristics
    Yurimi Lee, Kiyong Na, Ha Young Woo, Hyun-Soo Kim
    Diagnostics.2022; 12(5): 1102.     CrossRef
  • Exosomal MicroRNA Analyses in Esophageal Squamous Cell Carcinoma Cell Lines
    Sora Kim, Gwang Ha Kim, Su Jin Park, Chae Hwa Kwon, Hoseok I, Moon Won Lee, Bong Eun Lee
    Journal of Clinical Medicine.2022; 11(15): 4426.     CrossRef
  • Tailored point-of-care biosensors for liquid biopsy in the field of oncology
    Sima Singh, Pritam Saha Podder, Matt Russo, Charles Henry, Stefano Cinti
    Lab on a Chip.2022;[Epub]     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
    Pamela Abdayem, David Planchard
    European Respiratory Review.2021; 30(161): 200294.     CrossRef
  • Dynamics of Specific cfDNA Fragments in the Plasma of Full Marathon Participants
    Takehito Sugasawa, Shin-ichiro Fujita, Tomoaki Kuji, Noriyo Ishibashi, Kenshirou Tamai, Yasushi Kawakami, Kazuhiro Takekoshi
    Genes.2021; 12(5): 676.     CrossRef
  • Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
    Daniela Ferreira, Juliana Miranda, Paula Martins-Lopes, Filomena Adega, Raquel Chaves
    International Journal of Molecular Sciences.2021; 22(8): 3815.     CrossRef
  • Real-World Analysis of the EGFR Mutation Test in Tissue and Plasma Samples from Non-Small Cell Lung Cancer
    Hyunwoo Lee, Joungho Han, Yoon-La Choi
    Diagnostics.2021; 11(9): 1695.     CrossRef
  • Objective Quantitation of EGFR Protein Levels using Quantitative Dot Blot Method for the Prognosis of Gastric Cancer Patients
    Lei Xin, Fangrong Tang, Bo Song, Maozhou Yang, Jiandi Zhang
    Journal of Gastric Cancer.2021; 21(4): 335.     CrossRef
  • The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer
    D. Akhoundova, J. Mosquera Martinez, L. E. Musmann, C. Britschgi, C. Rütsche, M. Rechsteiner, E. Nadal, M. R. Garcia Campelo, A. Curioni-Fontecedro
    Journal of Clinical Medicine.2020; 9(11): 3674.     CrossRef
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim, Jin-Haeng Chung
J Pathol Transl Med. 2019;53(4):199-206.   Published online May 2, 2019
DOI: https://doi.org/10.4132/jptm.2019.04.24
Correction in: J Pathol Transl Med 2020;54(2):196
  • 11,812 View
  • 577 Download
  • 39 Citations
AbstractAbstract PDF
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer. Because each PD-1/PD-L1 blockade was approved together with a specific PD-L1 IHC assay used in the clinical trials, pathologists have been challenged with performing various assays with a limited sample. To provide a more unified understanding of this, several cross-validation studies between platforms have been performed and showed consistent results. However, the interchangeability of assays may be limited in practice because of the risk of misclassification of patients for the treatment. Furthermore, several issues, including the temporal and spatial heterogeneity of PD-L1 expression in the tumor, and the potential for cytology specimens to be used as an alternative to tissue samples for PD-L1 testing, have still not been resolved. In the future, one of the main aims of immunotherapy research should be to find a novel predictive biomarker for PD-1 blockade therapy and a way to combine it with PD-L1 IHC and other tests.

Citations

Citations to this article as recorded by  
  • Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
    Guanghui Gao, Longgang Cui, Fei Zhou, Tao Jiang, Wanying Wang, Shiqi Mao, Fengying Wu, Fangli Jiang, Bei Zhang, Ting Bei, Wenchuan Xie, Cheng Zhang, Hougang Zhang, Chan Gao, Xiaochen Zhao, Yuezong Bai, Caicun Zhou, Shengxiang Ren
    International Journal of Cancer.2023; 152(1): 79.     CrossRef
  • A targeted expression panel for classification, gene fusion detection and PD-L1 measurements – Can molecular profiling replace immunohistochemistry in non-small cell lung cancer?
    Anita Tranberg Simonsen, Amalie Utke, Johanne Lade-Keller, Lasse Westphal Thomsen, Torben Steiniche, Magnus Stougaard
    Experimental and Molecular Pathology.2022; 125: 104749.     CrossRef
  • Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review
    Swati Satturwar, Ilaria Girolami, Enrico Munari, Francesco Ciompi, Albino Eccher, Liron Pantanowitz
    Diagnostic Cytopathology.2022; 50(6): 313.     CrossRef
  • Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
    Yen-Yu Lin, Lei-Chi Wang, Yu-Han Hsieh, Yu-Ling Hung, Yung-An Chen, Yu-Chieh Lin, Yen-Yin Lin, Teh-Ying Chou
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
    Cristina-Florina Pirlog, Horia Teodor Cotan, Andreea Parosanu, Cristina Orlov Slavu, Ana Maria Popa, Cristian Iaciu, Mihaela Olaru, Alexandru Vlad Oprita, Irina Nita, Cornelia Nitipir
    Cureus.2022;[Epub]     CrossRef
  • Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
    Frédérique Penault-Llorca, Keith M. Kerr, Pilar Garrido, Erik Thunnissen, Elisabeth Dequeker, Nicola Normanno, Simon J. Patton, Jenni Fairley, Joshua Kapp, Daniëlle de Ridder, Aleš Ryška, Holger Moch
    Virchows Archiv.2022; 481(3): 351.     CrossRef
  • Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
    Chih-Cheng Tsao, Hsin-Hung Wu, Ying-Fu Wang, Po-Chien Shen, Wen-Ting Wu, Huang-Yun Chen, Yang-Hong Dai
    Biomedicines.2022; 10(7): 1539.     CrossRef
  • Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites
    Wenqi Ti, Tianhui Wei, Jianbo Wang, Yufeng Cheng
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Pan-cancer analysis of the angiotensin II receptor-associated protein as a prognostic and immunological gene predicting immunotherapy responses in pan-cancer
    Kai Hong, Yingjue Zhang, Lingli Yao, Jiabo Zhang, Xianneng Sheng, Lihua Song, Yu Guo, Yangyang Guo
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma
    Jiwon Koh, Haeryoung Kim, Kyung Chul Moon, Cheol Lee, Kyoungbun Lee, Han Suk Ryu, Kyeong Cheon Jung, Yoon Kyung Jeon
    American Journal of Surgical Pathology.2022;[Epub]     CrossRef
  • Molecular imaging of immune checkpoints in oncology: Current and future applications
    Shushan Ge, Tongtong Jia, Jihui Li, Bin Zhang, Shengming Deng, Shibiao Sang
    Cancer Letters.2022; 548: 215896.     CrossRef
  • PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
    Katerina Hadrava Vanova, Ondrej Uher, Leah Meuter, Suman Ghosal, Sara Talvacchio, Mayank Patel, Jiri Neuzil, Karel Pacak
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
    John Turchini, Loretta Sioson, Adele Clarkson, Amy Sheen, Anthony J. Gill
    Endocrine Pathology.2021; 32(3): 408.     CrossRef
  • Comprehensive tumor molecular profile analysis in clinical practice
    Mustafa Özdoğan, Eirini Papadopoulou, Nikolaos Tsoulos, Aikaterini Tsantikidi, Vasiliki-Metaxa Mariatou, Georgios Tsaousis, Evgenia Kapeni, Evgenia Bourkoula, Dimitrios Fotiou, Georgios Kapetsis, Ioannis Boukovinas, Nikolaos Touroutoglou, Athanasios Fassa
    BMC Medical Genomics.2021;[Epub]     CrossRef
  • CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study
    Zekun Jiang, Yinjun Dong, Linke Yang, Yunhong Lv, Shuai Dong, Shuanghu Yuan, Dengwang Li, Liheng Liu
    Journal of Digital Imaging.2021; 34(5): 1073.     CrossRef
  • Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics
    Pierre Murchan, Cathal Ó’Brien, Shane O’Connell, Ciara S. McNevin, Anne-Marie Baird, Orla Sheils, Pilib Ó Broin, Stephen P. Finn
    Diagnostics.2021; 11(8): 1406.     CrossRef
  • Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic
    David Leung, Samuel Bonacorsi, Ralph Adam Smith, Wolfgang Weber, Wendy Hayes
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma
    Jerónimo Rafael Rodríguez-Cid, Sonia Carrasco-Cara Chards, Iván Romarico González-Espinoza, Vanessa García-Montes, Julio César Garibay-Díaz, Osvaldo Hernández-Flores, Rodrigo Riera-Sala, Anna Gozalishvili-Boncheva, Jorge Arturo Alatorre-Alexander, Luis Ma
    Lung Cancer Management.2021;[Epub]     CrossRef
  • Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab
    Taisuke Araki, Kazunari Tateishi, Kei Sonehara, Shuko Hirota, Masamichi Komatsu, Manabu Yamamoto, Shintaro Kanda, Hiroshi Kuraishi, Masayuki Hanaoka, Tomonobu Koizumi
    Thoracic Cancer.2021; 12(5): 603.     CrossRef
  • Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis
    Qiong-ying Hu, Yun Yuan, Yu-chen Li, Lu-yao Yang, Xiang-yu Zhou, Da-qian Xiong, Zi-yi Zhao, Hiroshi Tanaka
    BioMed Research International.2021; 2021: 1.     CrossRef
  • PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study
    Belen Rubio-Viqueira, Margarita Majem Tarruella, Martín Lázaro, Sergio Vázquez Estévez, Juan Felipe Córdoba-Ortega, Inmaculada Maestu Maiques, Jorge García González, Ana Blasco Cordellat, Javier Valdivia-Bautista, Carmen González Arenas, Jose Miguel Sánch
    Lung Cancer Management.2021;[Epub]     CrossRef
  • Can Systems Biology Advance Clinical Precision Oncology?
    Andrea Rocca, Boris N. Kholodenko
    Cancers.2021; 13(24): 6312.     CrossRef
  • Do we need PD‐L1 as a biomarker for thyroid cytologic and histologic specimens?
    Marc P. Pusztaszeri, Massimo Bongiovanni, Fadi Brimo
    Cancer Cytopathology.2020; 128(3): 160.     CrossRef
  • Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
    Andrea Botticelli, Pamela Vernocchi, Federico Marini, Andrea Quagliariello, Bruna Cerbelli, Sofia Reddel, Federica Del Chierico, Francesca Di Pietro, Raffaele Giusti, Alberta Tomassini, Ottavia Giampaoli, Alfredo Miccheli, Ilaria Grazia Zizzari, Marianna
    Journal of Translational Medicine.2020;[Epub]     CrossRef
  • Immune checkpoint inhibitors in advanced non–small cell lung cancer: A metacentric experience from India
    Santosh Kumar, Srujana Joga, Bivas Biswas, Deepak Dabkara, Kuruswamy Thurai Prasad, Navneet Singh, Prabhat Singh Malik, Sachin Khurana, Sandip Ganguly, Valliappan Muthu, Ullas Batra
    Current Problems in Cancer.2020; 44(3): 100549.     CrossRef
  • Utility of CT radiomics for prediction of PD‐L1 expression in advanced lung adenocarcinomas
    Jiyoung Yoon, Young Joo Suh, Kyunghwa Han, Hyoun Cho, Hye‐Jeong Lee, Jin Hur, Byoung Wook Choi
    Thoracic Cancer.2020; 11(4): 993.     CrossRef
  • Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm
    Lars H. Breimer, Petros Nousios, Louise Olsson, Hans Brunnström
    Scandinavian Journal of Clinical and Laboratory Investigation.2020; 80(5): 360.     CrossRef
  • Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
    Jean-David Fumet, Caroline Truntzer, Mark Yarchoan, Francois Ghiringhelli
    European Journal of Cancer.2020; 131: 40.     CrossRef
  • Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
    Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
    Cancers.2020; 12(5): 1125.     CrossRef
  • Current status and future perspectives of liquid biopsy in non-small cell lung cancer
    Sunhee Chang, Jae Young Hur, Yoon-La Choi, Chang Hun Lee, Wan Seop Kim
    Journal of Pathology and Translational Medicine.2020; 54(3): 204.     CrossRef
  • Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record
    Fabio Pagni, Umberto Malapelle, Claudio Doglioni, Gabriella Fontanini, Filippo Fraggetta, Paolo Graziano, Antonio Marchetti, Elena Guerini Rocco, Pasquale Pisapia, Elena V. Vigliar, Fiamma Buttitta, Marta Jaconi, Nicola Fusco, Massimo Barberis, Giancarlo
    Cancers.2020; 12(7): 1800.     CrossRef
  • PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Ana Bocanegra, Ester Blanco, Gonzalo Fernandez-Hinojal, Hugo Arasanz, Luisa Chocarro, Miren Zuazo, Pilar Morente, Ruth Vera, David Escors, Grazyna Kochan
    International Journal of Molecular Sciences.2020; 21(16): 5918.     CrossRef
  • PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
    Danny Rischin, Marta Gil-Martin, Antonio González-Martin, Irene Braña, June Y. Hou, Daniel Cho, Gerald S. Falchook, Silvia Formenti, Salma Jabbour, Kathleen Moore, Aung Naing, Kyriakos P. Papadopoulos, Joaquina Baranda, Wen Fury, Minjie Feng, Elizabeth St
    Gynecologic Oncology.2020; 159(2): 322.     CrossRef
  • Atezolizumab: A Review in Extensive-Stage SCLC
    James E. Frampton
    Drugs.2020; 80(15): 1587.     CrossRef
  • Prognostic and clinicopathological roles of programmed death‐ligand 1 ( PD‐L1 ) expression in thymic epithelial tumors: A meta‐analysis
    Hyun Min Koh, Bo Gun Jang, Hyun Ju Lee, Chang Lim Hyun
    Thoracic Cancer.2020; 11(11): 3086.     CrossRef
  • Präzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten
    Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vollome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco, Luca Longo, Lodovica Zullo, Enrica Teresa Tanda, Chiara Dellepiane, Paolo Pronzato
    Kompass Pneumologie.2020; 8(6): 300.     CrossRef
  • Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
    Lee, Kim, Sung, Lee, Han, Kim, Choi
    International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef
  • Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers
    João Lobo, Ângelo Rodrigues, Rita Guimarães, Mariana Cantante, Paula Lopes, Joaquina Maurício, Jorge Oliveira, Carmen Jerónimo, Rui Henrique
    Cancers.2019; 11(10): 1535.     CrossRef
  • Basis of PD1/PD-L1 Therapies
    Barbara Seliger
    Journal of Clinical Medicine.2019; 8(12): 2168.     CrossRef
Original Articles
Association between Expression of 8-OHdG and Cigarette Smoking in Non-small Cell Lung Cancer
Ae Ri An, Kyoung Min Kim, Ho Sung Park, Kyu Yun Jang, Woo Sung Moon, Myoung Jae Kang, Yong Chul Lee, Jong Hun Kim, Han Jung Chae, Myoung Ja Chung
J Pathol Transl Med. 2019;53(4):217-224.   Published online March 11, 2019
DOI: https://doi.org/10.4132/jptm.2019.02.20
  • 5,252 View
  • 217 Download
  • 8 Citations
AbstractAbstract PDF
Background
Exposure to cigarette smoking (CS) is a major risk factor for the development of lung cancer. CS is known to cause oxidative DNA damage and mutation of tumor-related genes, and these factors are involved in carcinogenesis. 8-Hydroxydeoxyguanosine (8-OHdG) is considered to be a reliable biomarker for oxidative DNA damage. Increased levels of 8-OHdG are associated with a number of pathological conditions, including cancer. There are no reports on the expression of 8-OHdG by immunohistochemistry in non-small cell lung cancer (NSCLC).
Methods
We investigated the expression of 8-OHdG and p53 in 203 NSCLC tissues using immunohistochemistry and correlated it with clinicopathological features including smoking.
Results
The expression of 8-OHdG was observed in 83.3% of NSCLC. It was significantly correlated with a low T category, negative lymph node status, never-smoker, and longer overall survival (p < .05) by univariate analysis. But multivariate analysis revealed that 8-OHdG was not an independent prognostic factor for overall survival in NSCLC patients. The aberrant expression of p53 significantly correlated with smoking, male, squamous cell carcinoma, and Ki-67 positivity (p < .05).
Conclusions
The expression of 8-OHdG was associated with good prognostic factors. It was positively correlated with never-smokers in NSCLC, suggesting that oxidative damage of DNA cannot be explained by smoking alone and may depend on complex control mechanisms.

Citations

Citations to this article as recorded by  
  • Serum 8-Hydroxy-2′-deoxyguanosine Predicts Severity and Prognosis of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
    Peng Cao, Chen Zhang, Dong-Xu Hua, Meng-Die Li, Bian-Bian Lv, Lin Fu, Hui Zhao
    Lung.2022; 200(1): 31.     CrossRef
  • Redox signaling at the crossroads of human health and disease
    Jing Zuo, Zhe Zhang, Maochao Luo, Li Zhou, Edouard C. Nice, Wei Zhang, Chuang Wang, Canhua Huang
    MedComm.2022;[Epub]     CrossRef
  • Assessment of MDA and 8-OHdG expressions in ovine pulmonary adenocarcinomas by immunohistochemical and immunofluorescence methods
    Emin Karakurt, Enver Beytut, Serpil Dağ, Hilmi Nuhoğlu, Ayfer Yıldız, Emre Kurtbaş
    Acta Veterinaria Brno.2022; 91(3): 235.     CrossRef
  • Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
    Henry Jay Forman, Hongqiao Zhang
    Nature Reviews Drug Discovery.2021; 20(9): 689.     CrossRef
  • Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population
    Mikhlid H. Almutairi, Bader O. Almutairi, Turki M. Alrubie, Sultan N. Alharbi, Narasimha R. Parine, Abdulwahed F. Alrefaei, Ibrahim Aldeailej, Abdullah Alamri, Abdelhabib Semlali, Alvaro Galli
    PLOS ONE.2021; 16(1): e0245133.     CrossRef
  • Measurement of uranium concentrations in urine samples of adult healthy groups in Najaf governorate with estimation of urine concentrations of 8-OHdG compound as biomarker for DNA damage
    Samia K. Abbas, Dhuha S. Saleh, Hayder S. Hussain
    Journal of Physics: Conference Series.2021; 1879(3): 032097.     CrossRef
  • Common Data Model and Database System Development for the Korea Biobank Network
    Soo-Jeong Ko, Wona Choi, Ki-Hoon Kim, Seo-Joon Lee, Haesook Min, Seol-Whan Oh, In Young Choi
    Applied Sciences.2021; 11(24): 11825.     CrossRef
  • EVALUATION OF OXIDATIVE STATUS IN PATIENTS WITH CHRONIC PERIODONTITIS AND ADDITIONAL TOBACCO ABUSE: A CROSS-SECTIONAL STUDY
    Didem ÖZKAL EMİNOĞLU, Varol ÇANAKÇI
    Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi.2020; : 1.     CrossRef
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
Yeon Bi Han, Hyun Jung Kwon, Soo Young Park, Eun-Sun Kim, Hyojin Kim, Jin-Haeng Chung
J Pathol Transl Med. 2019;53(2):86-93.   Published online January 14, 2019
DOI: https://doi.org/10.4132/jptm.2018.12.26
  • 4,639 View
  • 128 Download
  • 1 Citations
AbstractAbstract PDF
Background
Both human leukocyte antigen (HLA) class I and programmed death-ligand 1 (PD-L1) molecules are known to play important roles in cancer immunity. In this study, we evaluated HLA class I expression in resected adenocarcinoma of the lung, and investigated its prognostic impact in correlation with PD-L1 expression.
Methods
HLA class I and PD-L1 expression was evaluated by immunohistochemistry in a total of 403 resected lung adenocarcinomas using tissue microarray. Correlations between the expression of HLA class I/PD-L1 and clinicopathologic features and prognostic significance were analyzed.
Results
HLA class I expression was reduced in 91.6% of adenocarcinoma, and more frequently reduced in patients with younger age, absence of vascular invasion, and low pathologic stage (p = .033, p = .007, and p = .012, respectively). Positive PD-L1 expression in tumor cells was 16.1% (1% cut-off), and associated with poor differentiation, presence of vascular invasion and nodal metastasis (p < .001, p = .002, and p = .032, respectively). On survival analysis, HLA class I or PD-L1 expression alone did not show any statistical significance. On the integrated analysis, HLA class I (+)/PD-L1 (+) subgroup showed a significantly shorter overall survival than other groups (p = .001). Multivariate analysis revealed that coexpression of HLA class I and PD-L1 was an independent poor prognostic factor of lung adenocarcinoma. (p < .001; hazard ratio, 6.106; 95% confidence interval, 2.260 to 16.501).
Conclusions
Lung adenocarcinoma with coexpression of HLA class I and PD-L1 was associated with poor prognosis. This subgroup may evade immune attack by expressing PD-L1 protein despite HLA expression.

Citations

Citations to this article as recorded by  
  • Loss of HLA-class-I expression in non-small-cell lung cancer: Association with prognosis and anaerobic metabolism
    Ioannis M. Koukourakis, Alexandra Giatromanolaki, Achilleas Mitrakas, Michael I. Koukourakis
    Cellular Immunology.2022; 373: 104495.     CrossRef
Prognostic Role of S100A8 and S100A9 Protein Expressions in Non-small Cell Carcinoma of the Lung
Hyun Min Koh, Hyo Jung An, Gyung Hyuck Ko, Jeong Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Sung Hwan Kim, Kyung Nyeo Jeon, Gyeong-Won Lee, Se Min Jang, Dae Hyun Song
J Pathol Transl Med. 2019;53(1):13-22.   Published online November 26, 2018
DOI: https://doi.org/10.4132/jptm.2018.11.12
  • 5,657 View
  • 222 Download
  • 6 Citations
AbstractAbstract PDF
Background
S100A8 and S100A9 have been gaining recognition for modulating tumor growthand metastasis. This study aimed at evaluating the clinical significance of S100A8 and S100A9 innon-small cell lung cancer (NSCLC).
Methods
We analyzed the relationship between S100A8and S100A9 expressions, clinicopathological characteristics, and prognostic significance in tumorcells and peritumoral inflammatory cells.
Results
The positive staining of S100A8 in tumorcells was significantly increased in male (p < .001), smoker (p = .034), surgical method other thanlobectomy (p = .024), squamous cell carcinoma (SQCC) (p < .001) and higher TNM stage (p = .022)compared with female, non-smoker, lobectomy, adenocarcinoma (ADC), and lower stage. Theproportion of tumor cells stained for S100A8 was related to histologic type (p < .001) and patientsex (p = .027). The proportion of inflammatory cells stained for S100A8 was correlated with patientage (p = .022), whereas the proportion of inflammatory cells stained for S100A9 was correlatedwith patient sex (p < .001) and smoking history (p = .031). Moreover, positive staining in tumorcells, more than 50% of the tumor cells stained and less than 30% of the inflammatory cellsstained for S100A8 and S100A9 suggested a tendency towards increased survivability in SQCCbut towards decreased survivability in ADC.
Conclusions
S100A8 and S100A9 expressions might be potential prognostic markers in patients with NSCLC.

Citations

Citations to this article as recorded by  
  • A Prognostic Gene Signature for Hepatocellular Carcinoma
    Rong Chen, Meng Zhao, Yanli An, Dongfang Liu, Qiusha Tang, Gaojun Teng
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Gene expression related to lung cancer altered by PHMG-p treatment in PBTE cells
    Yoon Hee Park, Sang Hoon Jeong, Hyejin Lee, Cherry Kim, Yoon Jeong Nam, Ja Young Kang, Jin Young Choi, Yu-Seon Lee, Su A. Park, Jaeyoung Kim, Eun-Kee Park, Yong-Wook Baek, Hong Lee, Ju-Han Lee
    Molecular & Cellular Toxicology.2022;[Epub]     CrossRef
  • The S100 protein family in lung cancer
    Ting Wang, Ge Du, Dong Wang
    Clinica Chimica Acta.2021; 520: 67.     CrossRef
  • The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study
    Hong-Yan Liu, Hui-Xian Xiang, Ying Xiang, Zheng Xu, Chun-Mei Feng, Jun Fei, Lin Fu, Hui Zhao
    BMC Infectious Diseases.2021;[Epub]     CrossRef
  • Saliva proteomic analysis reveals possible biomarkers of renal cell carcinoma
    Xiao Li Zhang, Zheng Zhi Wu, Yun Xu, Ji Guo Wang, Yong Qiang Wang, Mei Qun Cao, Chang Hao Wang
    Open Chemistry.2020; 18(1): 918.     CrossRef
  • Prognostic Role of S100A8 in Human Solid Cancers: A Systematic Review and Validation
    An Huang, Wei Fan, Jiacui Liu, Ben Huang, Qingyuan Cheng, Ping Wang, Yiping Duan, Tiantian Ma, Liangyue Chen, Yanping Wang, Mingxia Yu
    Frontiers in Oncology.2020;[Epub]     CrossRef
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Bo Mi Ku, Mi Hwa Heo, Joo-Hang Kim, Byoung Chul Cho, Eun Kyung Cho, Young Joo Min, Ki Hyeong Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Tae Jung Kim, Ho Yun Lee, Hojoong Kim, Kyung-Jong Lee, Myung-Ju Ahn
J Pathol Transl Med. 2018;52(3):148-156.   Published online March 26, 2018
DOI: https://doi.org/10.4132/jptm.2018.03.12
  • 6,329 View
  • 281 Download
  • 12 Citations
AbstractAbstract PDF
Background
Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might help predict patient outcomes and guide treatment. The aim of this study was to evaluate the clinical adequacy of molecular testing using next-generation sequencing (NGS) for small biopsy samples and characterize the mutational landscape of Korean patients with advanced NSCLC.
Methods
DNA was extracted from small biopsy samples of 162 patients with advanced NSCLC. Targeted NGS of genomic alterations was conducted using Ion AmpliSeq Cancer Hotspot Panel v2.
Results
The median age of patients was 64 years (range, 32 to 83 years) and the majority had stage IV NSCLC at the time of cancer diagnosis (90%). Among the 162 patients, 161 patients (99.4%) had novel or hotspot mutations (range, 1 to 21 mutated genes). Mutations were found in 41 genes. Three of the most frequently mutated genes were TP53 (151, 93.2%), KDR (104, 64.2%), and epidermal growth factor receptor (EGFR; 69, 42.6%). We also observed coexistence of EGFR and other oncogene (such as KRAS, PIC3CA, PTEN, and STK11) mutations. Given that 69.6% (48/69) of EGFR mutant patients were treated with EGFR tyrosine kinase inhibitors, EGFR mutant status had higher prognostic ability in this study.
Conclusions
These results suggest that targeted NGS using small biopsy samples is feasible and allows for the detection of both common and rare mutations in NSCLC.

Citations

Citations to this article as recorded by  
  • Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis
    Barbara Melosky, Kato Kambartel, Maik Häntschel, Margherita Bennetts, Dana J. Nickens, Julia Brinkmann, Antonin Kayser, Michael Moran, Federico Cappuzzo
    Molecular Diagnosis & Therapy.2022; 26(1): 7.     CrossRef
  • Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
    Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
    Journal of Pathology and Translational Medicine.2022; 56(5): 249.     CrossRef
  • Suitability of transbronchial brushing cytology specimens for next‐generation sequencing in peripheral lung cancer
    Naoki Furuya, Shingo Matsumoto, Kazutaka Kakinuma, Kei Morikawa, Takeo Inoue, Hisashi Saji, Koichi Goto, Masamichi Mineshita
    Cancer Science.2021; 112(1): 380.     CrossRef
  • KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway
    Yitong Xu, Chenglong Wang, Xizi Jiang, Yao Zhang, Hongbo Su, Jun Jiang, Hongjiu Ren, Xueshan Qiu
    Cell Death & Disease.2021;[Epub]     CrossRef
  • Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
    Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
    Journal of Pathology and Translational Medicine.2021; 55(3): 181.     CrossRef
  • Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
    Quincy S. Chu
    Therapeutic Advances in Medical Oncology.2020; 12: 175883591989575.     CrossRef
  • Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients


    Hengrui Liang, Caichen Li, Yi Zhao, Shen Zhao, Jun Huang, Xiuyu Cai, Bo Cheng, Shan Xiong, Jianfu Li, Wei Wang, Changbin Zhu, Weiwei Li, Jianxing He, Wenhua Liang
    Cancer Management and Research.2020; Volume 12: 8653.     CrossRef
  • Prognostic role of Rab27A and Rab27B expression in patients with non-small cell lung carcinoma
    Hyun Min Koh, Dae Hyun Song
    Thoracic Cancer.2019; 10(2): 143.     CrossRef
  • PD-L1 expression inROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening ofEGFR,ALK, andROS1
    Jongmin Lee, Chan Kwon Park, Hyoung-Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae-Jung Kim
    Thoracic Cancer.2019; 10(1): 103.     CrossRef
  • Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer
    Hersh A. Ham-Karim, Henry Okuchukwu Ebili, Kirsty Manger, Wakkas Fadhil, Narmeen S. Ahmad, Susan D. Richman, Mohammad Ilyas
    Molecular Diagnosis & Therapy.2019; 23(3): 383.     CrossRef
  • Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing
    Hidenori Kage, Shinji Kohsaka, Aya Shinozaki‐Ushiku, Yoshihisa Hiraishi, Jiro Sato, Kazuhiro Nagayama, Tetsuo Ushiku, Daiya Takai, Jun Nakajima, Kiyoshi Miyagawa, Hiroyuki Aburatani, Hiroyuki Mano, Takahide Nagase
    Cancer Science.2019; 110(8): 2652.     CrossRef
  • PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
    Anastasios Gkountakos, Giulia Sartori, Italia Falcone, Geny Piro, Ludovica Ciuffreda, Carmine Carbone, Giampaolo Tortora, Aldo Scarpa, Emilio Bria, Michele Milella, Rafael Rosell, Vincenzo Corbo, Sara Pilotto
    Cancers.2019; 11(8): 1141.     CrossRef
Prognostic Significance of Aquaporin 5 Expression in Non-small Cell Lung Cancer
Young Min Jo, Tae In Park, Hwa Young Lee, Ji Yun Jeong, Won Kee Lee
J Pathol Transl Med. 2016;50(2):122-128.   Published online February 8, 2016
DOI: https://doi.org/10.4132/jptm.2015.10.31
  • 10,330 View
  • 75 Download
  • 8 Citations
AbstractAbstract PDF
Background
Aquaporins are water channel proteins that play a major role in the movement of water in various human tissues. Recently, it has been found that aquaporins have influence in the carcinogenesis of human malignancies. We analyzed the prognostic impact of aquaporin 5 (AQP5) in non-small lung cancer (NSCLC). Methods: Seventy-six cases of NSCLC were studied, including 44 cases of adenocarcinoma (ADC) and 32 cases of squamous cell carcinoma (SQCC). Tissue microarray was constructed and immunohistochemical staining for AQP5 was performed. Results: AQP5 was positive in 59.2% of the total enrolled NSCLCs (63.7% in ADC and 53.1% in SQCC). The difference in expression of AQP5 according to the histologic grade of the tumor was significant (p<.047), but not in a serial order. When ADC and SQCC were separately evaluated, no significant difference was observed according to the histologic grade of the tumor (p=.076 in ADC and p=.631 in SQCC). No difference was observed between AQP5 expression and other demographic data and tumor characteristics. Disease-free survival (DFS) was higher in AQP5 negative cases than positive cases in ADC (p=.047), but no significance was found in SQCC (p=.068). We were unable to find a significance between AQP5 overexpression and overall survival in either ADC (p=.210) or SQCC (p=.533). Conclusions: AQP5 expression is associated with DFS in ADC of the lung and tumor grade of NSCLC. The present study suggests that AQP5 can be a prognostic factor of NSCLC.

Citations

Citations to this article as recorded by  
  • Aquaporins 1, 3 and 5 in Different Tumors, their Expression, Prognosis Value and Role as New Therapeutic Targets
    Mahdieh-Sadat Moosavi, Yalda Elham
    Pathology & Oncology Research.2020; 26(2): 615.     CrossRef
  • Aquaporins in lung health and disease: Emerging roles, regulation, and clinical implications
    Ekta Yadav, Niket Yadav, Ariel Hus, Jagjit S. Yadav
    Respiratory Medicine.2020; 174: 106193.     CrossRef
  • Combined Systematic Review and Transcriptomic Analyses of Mammalian Aquaporin Classes 1 to 10 as Biomarkers and Prognostic Indicators in Diverse Cancers
    Pak Hin Chow, Joanne Bowen, Andrea J Yool
    Cancers.2020; 12(7): 1911.     CrossRef
  • Prognostic Role of S100A8 and S100A9 Protein Expressions in Non-small Cell Carcinoma of the Lung
    Hyun Min Koh, Hyo Jung An, Gyung Hyuck Ko, Jeong Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Sung Hwan Kim, Kyung Nyeo Jeon, Gyeong-Won Lee, Se Min Jang, Dae Hyun Song
    Journal of Pathology and Translational Medicine.2019; 53(1): 13.     CrossRef
  • Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer‐associated fibroblasts
    Ahmed E Hegab, Mari Ozaki, Naofumi Kameyama, Jingtao Gao, Shizuko Kagawa, Hiroyuki Yasuda, Kenzo Soejima, Yongjun Yin, Robert D Guzy, Yoshikazu Nakamura, David M Ornitz, Tomoko Betsuyaku
    The Journal of Pathology.2019; 249(2): 193.     CrossRef
  • Anti-cancer effect of Aquaporin 5 silencing in colorectal cancer cells in association with inhibition of Wnt/β-catenin pathway
    Wei Wang, Qing Li, Tao Yang, Dongsheng Li, Feng Ding, Hongzhi Sun, Guang Bai
    Cytotechnology.2018; 70(2): 615.     CrossRef
  • Knockdown of aquaporin-5 sensitizes colorectal cancer cells to 5-fluorouracil via inhibition of the Wnt–β-catenin signaling pathway
    Qing Li, Tao Yang, Dongsheng Li, Feng Ding, Guang Bai, Wei Wang, Hongzhi Sun
    Biochemistry and Cell Biology.2018; 96(5): 572.     CrossRef
  • Implications of KRAS mutations in acquired resistance to treatment in NSCLC
    Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, Elena Arrigoni, Stefano Fogli, Massimo Di Maio, Iacopo Petrini, Romano Danesi
    Oncotarget.2018; 9(5): 6630.     CrossRef
Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer
Ho Won Lee, Eui Han Kim, Mee-Hye Oh
Korean J Pathol. 2012;46(5):470-477.   Published online October 25, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.5.470
  • 7,322 View
  • 25 Download
  • 12 Citations
AbstractAbstract PDF
Background

Ezrin, a member of the ezrin-radixin-moesin family, is implicated in tumor progression, metastatic dissemination, and adverse outcomes, in several cancer types. In this study, we explored the clinicopathological significance of ezrin expression in non-small cell lung carcinomas (NSCLCs).

Methods

Immunohistochemical analysis of tissue microarray with 112 surgically resected NSCLC specimens, was performed to examine the ezrin expression. We also correlated ezrin expression with other clinicopathological features and prognosis.

Results

The ezrin-positive group revealed significantly higher correlation with pleural invasion (p=0.016) and pathologic stage (p=0.050). Univariate survival analysis showed that ezrin-positive group had a significantly shorter cancer-specific survival than ezrin-negative group (p=0.016). Meanwhile, female (p=0.030), no pleural invasion (p=0.023), no lymphatic invasion (p=0.026), and early pathologic stage (p=0.008) significantly correlated with longer survival. Multivariate survival analysis showed that variables such as ezrin positivity (p=0.032), female (p=0.035), and early pathologic stage (p=0.001) were independent prognostic factors for NSCLC.

Conclusions

Ezrin might be a molecular marker to predict poor prognosis of NSCLC.

Citations

Citations to this article as recorded by  
  • Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation
    José Miguel Pardo-Sánchez, Nuria Mancheño, José Cerón, Carlos Jordá, Emilio Ansotegui, Óscar Juan, Sarai Palanca, Antonio Cremades, Carolina Gandía, Rosa Farràs
    Cancers.2021; 13(12): 2980.     CrossRef
  • Loss of ARID1A expression is associated with poor prognosis in non-small cell lung cancer
    Si-Hyong Jang, Ji-Hye Lee, Hyun Ju Lee, Hyundeuk Cho, Hyein Ahn, In Hag Song, Mee-Hye Oh
    Pathology - Research and Practice.2020; 216(11): 153156.     CrossRef
  • Ezrin Mediates Invasion and Metastasis in Tumorigenesis: A Review
    Yanan Song, Xiaokun Ma, Miao Zhang, Menghan Wang, Guoyu Wang, Ying Ye, Wei Xia
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma
    Thomas Cash, Hong Yin, Courtney McCracken, Zhi Geng, Steven G. DuBois, Bahig M. Shehata, Thomas A. Olson, Howard M. Katzenstein, Cynthia Wetmore
    Sarcoma.2017; 2017: 1.     CrossRef
  • Prognostic and Clinicopathological Significance of Transducer-Like Enhancer of Split 1 Expression in Gastric Cancer
    Ji-Hye Lee, Myoung-Won Son, Kyung-Ju Kim, Mee-Hye Oh, Hyundeuk Cho, Hyun Ju Lee, Si-Hyong Jang, Moon Soo Lee
    Journal of Gastric Cancer.2016; 16(1): 21.     CrossRef
  • Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma
    XIN LIU, DONGDONG QI, JUJIE QI, ZESHU MAO, XIANGDAN LI, JINHUI ZHANG, JINZI LI, WENBIN GAO
    Oncology Reports.2016; 35(1): 155.     CrossRef
  • Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma
    Nazia Syed, Sandip Chavan, Nandini A. Sahasrabuddhe, Santosh Renuse, Gajanan Sathe, Vishalakshi Nanjappa, Aneesha Radhakrishnan, Remya Raja, Sneha M. Pinto, Anand Srinivasan, T. S. Keshava Prasad, Kotteazeth Srikumar, Harsha Gowda, Vani Santosh, David Sid
    PROTEOMICS.2015; 15(2-3): 383.     CrossRef
  • Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis
    Jianwei Li, Kuanhai Wei, Hailang Yu, Dan Jin, Gang Wang, Bin Yu
    Scientific Reports.2015;[Epub]     CrossRef
  • Radixin Enhances Colon Cancer Cell Invasion by Increasing MMP-7 Production via Rac1-ERK Pathway
    Qi-Hong Jiang, Ai-Xiang Wang, Yan Chen
    The Scientific World Journal.2014; 2014: 1.     CrossRef
  • Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma
    Yisila Mu, Haoshaqiang Zhang, Lixin Che, Kun Li
    Medical Oncology.2014;[Epub]     CrossRef
  • Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer
    Tiefeng Jin, Jingchun Jin, Xiangyu Li, Songnan Zhang, Yun Ho Choi, Yingshi Piao, Xionghu Shen, Zhenhua Lin
    BMC Cancer.2014;[Epub]     CrossRef
  • Prognostic Value of Ezrin in Solid Tumors: A Meta-Analysis of the Literature
    Kun Han, WeiXiang Qi, ZhiHua Gan, Zan Shen, Yang Yao, DaLiu Min, Yves St-Pierre
    PLoS ONE.2013; 8(7): e68527.     CrossRef
The Histone Acetyltransferase hMOF is Overexpressed in Non-small Cell Lung Carcinoma.
Joon Seon Song, Sung Min Chun, Ji Young Lee, Dong Kwan Kim, Yong Hee Kim, Se Jin Jang
Korean J Pathol. 2011;45(4):386-396.
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.4.386
  • 3,907 View
  • 48 Download
  • 12 Citations
AbstractAbstract PDF
BACKGROUND
One of the histone acetyltransferases (HATs) family of proteins, human MOF (hMOF, MYST1), is involved in histone H4 acetylation, particularly at lysine 16 (H4K16Ac), an epigenetic mark of active genes. Dysregulation of the epigenetic mark influences cellular biology and possibly leads to oncogenesis. We examined the involvement of hMOF and H4K16Ac in primary non-small cell lung cancer (NSCLC).
METHODS
Reverse transcription polymerase chain reaction using fresh-frozen lung cancer tissues and lung cancer cell lines and immunohistochemistry for hMOF and H4K16Ac via tissue microarray of 551 formalin-fixed paraffin-embedded NSCLC tissue blocks were conducted.
RESULTS
hMOF mRNA was frequently overexpressed in lung cancer tissues, compared with normal lung tissues (10/20, 50%). NSCLC tissues were positive for hMOF in 37.6% (184/489) and H4K16Ac in 24.7% (122/493) of cases. hMOF protein expression was tightly correlated with the H4K16Ac level in tumors (p<0.001). Knockdown of hMOF mRNA with siRNA led to a significant inhibition of growth in the Calu-6 cell line.
CONCLUSIONS
hMOF was frequently expressed in NSCLC and was correlated with H4K16Ac. To our knowledge, this is the first study that has focused on the expression status of HATs and hMOF in NSCLC. Our results clearly suggest a potential oncogenic role of the gene and support its utility as a potential therapeutic target.

Citations

Citations to this article as recorded by  
  • The Biological Significance of Targeting Acetylation-Mediated Gene Regulation for Designing New Mechanistic Tools and Potential Therapeutics
    Chenise O’Garro, Loveth Igbineweka, Zonaira Ali, Mihaly Mezei, Shiraz Mujtaba
    Biomolecules.2021; 11(3): 455.     CrossRef
  • Histone Acetyltransferase MOF Orchestrates Outcomes at the Crossroad of Oncogenesis, DNA Damage Response, Proliferation, and Stem Cell Development
    Mayank Singh, Albino Bacolla, Shilpi Chaudhary, Clayton R. Hunt, Shruti Pandita, Ravi Chauhan, Ashna Gupta, John A. Tainer, Tej K. Pandita
    Molecular and Cellular Biology.2020;[Epub]     CrossRef
  • The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis
    Jiaming Su, Fei Wang, Yong Cai, Jingji Jin
    International Journal of Molecular Sciences.2016; 17(1): 99.     CrossRef
  • Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma
    LIN ZHU, JIAXING YANG, LINHONG ZHAO, XUE YU, LINGYAO WANG, FEI WANG, YONG CAI, JINGJI JIN
    International Journal of Oncology.2015; 46(6): 2535.     CrossRef
  • Arsenic Trioxide Reduces Global Histone H4 Acetylation at Lysine 16 through Direct Binding to Histone Acetyltransferase hMOF in Human Cells
    Da Liu, Donglu Wu, Linhong Zhao, Yang Yang, Jian Ding, Liguo Dong, Lianghai Hu, Fei Wang, Xiaoming Zhao, Yong Cai, Jingji Jin, Tim Thomas
    PLOS ONE.2015; 10(10): e0141014.     CrossRef
  • The histone acetyltransferase hMOF suppresses hepatocellular carcinoma growth
    Jin Zhang, Hui Liu, Hao Pan, Yuan Yang, Gang Huang, Yun Yang, Wei-Ping Zhou, Ze-Ya Pan
    Biochemical and Biophysical Research Communications.2014; 452(3): 575.     CrossRef
  • Regulation and function of histone acetyltransferase MOF
    Yang Yang, Xiaofei Han, Jingyun Guan, Xiangzhi Li
    Frontiers of Medicine.2014; 8(1): 79.     CrossRef
  • The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer
    Zhiwei Chen, Xiangyun Ye, Naiwang Tang, Shengping Shen, Ziming Li, Xiaomin Niu, Shun Lu, Ling Xu
    British Journal of Pharmacology.2014; 171(13): 3196.     CrossRef
  • Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma
    LINGLING CAO, LIN ZHU, JIAXING YANG, JIAMING SU, JINSONG NI, YUJUN DU, DA LIU, YANFANG WANG, FEI WANG, JINGJI JIN, YONG CAI
    International Journal of Oncology.2014; 44(4): 1207.     CrossRef
  • Coactivator MYST1 Regulates Nuclear Factor-κB and Androgen Receptor Functions During Proliferation of Prostate Cancer Cells
    Anbalagan Jaganathan, Pratima Chaurasia, Guang-Qian Xiao, Marc Philizaire, Xiang Lv, Shen Yao, Kerry L. Burnstein, De-Pei Liu, Alice C. Levine, Shiraz Mujtaba
    Molecular Endocrinology.2014; 28(6): 872.     CrossRef
  • A potential diagnostic marker for ovarian cancer: Involvement of the histone acetyltransferase, human males absent on the first
    NING LIU, RUI ZHANG, XIAOMING ZHAO, JIAMING SU, XIAOLEI BIAN, JINSONG NI, YING YUE, YONG CAI, JINGJI JIN
    Oncology Letters.2013; 6(2): 393.     CrossRef
  • Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma
    Yong Wang, Rui Zhang, Donglu Wu, Zhihua Lu, Wentao Sun, Yong Cai, Chunxi Wang, Jingji Jin
    Journal of Experimental & Clinical Cancer Research.2013;[Epub]     CrossRef
Clinicopathological Significance of S100A4 Expression in Non-small Cell Lung Carcinomas.
Eun Ah Jung, Hyun Deuk Cho, Ji Hye Lee, Mee Hye Oh
Korean J Pathol. 2010;44(5):477-482.
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.5.477
  • 2,979 View
  • 18 Download
  • 6 Citations
AbstractAbstract PDF
BACKGROUND
S100A4 has been implicated in invasion and metastasis of various malignant tumors. The aim of this study was to investigate whether or not S100A4 plays an important role in non-small cell lung carcinomas (NSCLCs).
METHODS
Sixty-seven patients with NSCLC including 37 with squamous cell carcinomas (SCCs) and 30 with adenocarcinomas (ADs) who had undergone surgical resection were analyzed. S100A4 expression was analyzed by immunohistochemistry using tissue microarray blocks.
RESULTS
S100A4 expression was positive in 56 (83.6%) of 67 NSCLC cases. ADs were more frequently S100A4 positive than SCCs (p = 0.017). However, no significant correlation was observed between S100A4 expression and age, gender, pT, pN or tumor, node and metastasis (TNM) stage. Two distant metastatic cases revealed an S100A4 positive reaction. Kaplan-Meier survival curves with the log-rank test showed no correlation with 3-year survival (p = 0.782) or 5-year survival (p = 0.227) in either group of patients according to S100A4 expression.
CONCLUSIONS
S100A4 expression was not correlated with age, gender, pT, pN or TNM stage or survival in patients with NSCLCs. Therefore, S100A4 expression may not be useful as a prognostic marker for NSCLCs. However, S100A4 expression showed a higher positivity in ADs than in SCCs.

Citations

Citations to this article as recorded by  
  • Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis
    Jing Zhang, Yanhui Gu, Xiaoli Liu, Ximin Rao, Guichuan Huang, Yao Ouyang
    Bioscience Reports.2020;[Epub]     CrossRef
  • S100A4 promotes endometrial cancer progress through epithelial-mesenchymal transition regulation
    TENG HUA, SHUANGGE LIU, XIAOYAN XIN, LIQIONG CAI, RUI SHI, SHUQI CHI, DILU FENG, HONGBO WANG
    Oncology Reports.2016; 35(6): 3419.     CrossRef
  • Prognostic value of cytoplasmic expression of S100A4 protein in endometrial carcinoma
    HYE IN CHONG, JEONG HEE LEE, MAN SOO YOON, DONG SOO SUH, KYUNGBIN KIM, JEE YEON KIM, KYUNG UN CHOI
    Oncology Reports.2014; 31(6): 2701.     CrossRef
  • Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma
    Hua Zhang, Jun Liu, Dongsheng Yue, Liuwei Gao, Daowei Wang, Hongdian Zhang, Changli Wang
    Journal of Clinical Pathology.2013; 66(11): 937.     CrossRef
  • Expression of S100A4, ephrin-A1 and osteopontin in non-small cell lung cancer
    Ane Kongsgaard Rud, Marius Lund-Iversen, Gisle Berge, Odd Terje Brustugun, Steinar K Solberg, Gunhild M Mælandsmo, Kjetil Boye
    BMC Cancer.2012;[Epub]     CrossRef
  • Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer
    Ho Won Lee, Eui Han Kim, Mee-Hye Oh
    Korean Journal of Pathology.2012; 46(5): 470.     CrossRef
Expression of p63 and its Isoform, deltaNp63, in Non-Small Cell Lung Carcinoma.
Ick Doo Kim, Dong Hoon Shin, Kyung Un Choi, Do Youn Park, Gi Yeong Huh, Mee Young Sol, Min Ki Lee, Young Dae Kim, Chang Hun Lee
Korean J Pathol. 2009;43(4):321-328.
DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.4.321
  • 2,868 View
  • 39 Download
AbstractAbstract PDF
BACKGROUND
Several studies have been conducted on the role of the p63 gene family in non-small cell lung carcinoma (NSCLC). Nevertheless, the role of these genes in the development and progression of NSCLC remains controversial. This study was designed to examine the expression and clinicopathologic significance of the p63 family in NSCLC.
METHODS
Immunohistochemical staining was performed on 92 cases of NSCLC (47 squamous cell carcinomas [SqCCs] and 45 adenocarcinomas [ACs]) using tissue microarray blocks. The results were analyzed and correlated with clinicopathologic data. RESULTS: The expression of delta Np63 (Delta Np63) was elevated in SqCC (39/47), but not in AC (2/45; p<0.01). Both p63 and Delta Np63 had high expression in 39 SqCCs; p63 and Delta Np63 also had a similar geomorphologic distribution in most positive tumors. The expression of Delta Np63 was correlated with histologic type, gender, pT stage, p53 expression, and p63 expression. pT and pN stages were independent factors in survival (p<0.05, respectively).
CONCLUSIONS
The major p63 isoform in NSCLC, Delta Np63, had a strong correlation with p53 and p63, and was exclusively expressed in SqCC. However, our findings suggest that Delta Np63 was not an independent prognostic factor for NSCLC.
Expression of p53 and Vascular Endothelial Growth Factor mRNA in Angiogenesis of Non-Small Cell Lung Carcinoma.
Jun Seog Kim, Tae In Park, Myoung Hoon Lee, Eun Kyoung Kwak, Ji Young Park, Jung Sik Kwak, Jong Min Chae
Korean J Pathol. 2003;37(1):35-40.
  • 1,409 View
  • 11 Download
AbstractAbstract PDF
BACKGROUND
Angiogenesis is one of the most important factors in the progression and me-tastasis of malignancies. Angiogenesis is a multistep process requiring the interaction of numerous factors able to stimulate the growth and development of new vessels. But, understanding of the mechanism involved in VEGF expression is unclear.
METHODS
Expressions of p53 and VEGF, and neovasculiarization were examined in 19 cases of surgically resected non-small cell carcinoma of the lung by the immunohistochemical staining. Furthermore, VEGF mRNA expressions were quantified in all cases using the real-time quantitative RT-PCR. These results were compared with clinicopathologic parameters such as histologic grade and stage.
RESULTS
Tumors with high aberrant p53 expressions showed significantly higher VEGF mRNA ex-pressions and microvessel counts than those with low p53 expressions. Expressions of p53 as well as VEGF and micovessel counts were closely associated with the tumor stage, but not with the histologic grade and other clinical parameters.
CONCLUSIONS
These results suggest that aberrant p53 expression may play a role in the regulation of VEGF expression and may be involved in controlling angiogenesis in non-small cell carcinoma of the lung.
An Analysis of HER-2/neu, ERCC1, and GST-pi in Advanced Non-Small Cell Lung Cancer Patients Who are Treated with Platinum-based Chemotherapy.
Kyung Jin Seo, Byoung Yong Shim, Hoon Kyo Kim, Ji Han Jung, Jinyoung Yoo, Seok Jin Kang, Kyo Young Lee
Korean J Pathol. 2008;42(6):327-334.
  • 1,470 View
  • 24 Download
AbstractAbstract PDF
BACKGROUND
Platinum-based chemotherapy has shown to be an effective first-line treatment for patients with advanced stage, unresectable non-small cell lung cancer (NSCLC). We evaluated the response rate to combination chemotherapy with cisplatin and taxane, and the significance of the HER-2/neu, ERCC1, and GST-pi status as predictive markers for the tumor response. METHODS: The HER-2/neu, ERCC1, and GST-pi status were analyzed in the biopsy specimens obtained from 35 patients with advanced stage NSCLC prior to cisplatin plus either paclitaxel or docetaxel chemotherapy. RESULTS: The response rate of the tumors to combination chemotherapy was 62.9% (22/35). HER-2/neu was amplified in 51.4% (18/35) of the tumors, and this was observed exclusively in patients with progressive disease (p=0.014). ERCC1 was overexpressed in 77.2% of the specimens (27/35), and this showed a tendency to correlate with the tumor response (p=0.057). GST-pi was detected in 85.7% of the specimens (30/35). Seventy-seven percent of the patients with a negative HER-2/neu and positive ERCC1 status showed a partial response, which was in contrast to only a 25% response rate for the patients with a positive HER-2/neu and negative ERCC1 status (p=0.006). The overall survival was prolonged in the patients without HER-2/neu amplification (15 vs 8.5 months, respectively, p=0.008). On multivariate analysis, the HER-2/neu status remained the significant predictor of survival (p=0.005). CONCLUSIONS: A combination of the ERCC1, HER-2/neu status may define a subset of patients with the most favorable response to combination chemotherapy regimens for treating advanced NSCLC.
Expression of p73 in Non-small Cell Lung Carcinomas.
Ji Han Jung, Gyeongsin Park, Chan Kwon Jung, Hyun Joo Choi, Jinyoung Yoo, Seok Jin Kang, Kyo Young Lee
Korean J Pathol. 2007;41(2):109-115.
  • 1,653 View
  • 19 Download
AbstractAbstract PDF
BACKGROUND
The p73 is a recently identified homologue of the tumor suppressor gene, p53, and it has been found to induce apoptosis and inhibit cell proliferation. However, its role in the development of tumors is unclear. This study examined the expression of p73 in patients with non-small cell lung carcinomas (NSCLCs) to determine its clinical significance and association with the expressions of p53, pRb, and mdm2.
METHODS
A total of 183 NSCLCs were analyzed immunohistochemically using a tissue microarray.
RESULTS
The p73 protein was expressed in the cell nuclei in 156 (85.2%) out of the 183 cases. There was no correlation between the p73 expression and the clinicopathological variables. However, there was a correlation between the p73 expression and the mdm2 and pRb expressions. Multivariate Cox survival analysis identified tumor size and lymph node metastasis to be independent prognostic factors, but the p73 expression was not found to be associated with the patients' survival.
CONCLUSIONS
p73 is commonly expressed in NSCLC and it might, in conjunction with pRb and mdm2, be involved in the development of these tumors.
The Expression of Telomerase Reverse Transcriptase Protein is an Independent Prognostic Marker in Early Stage Non-Small Cell Lung Carcinomas.
Ji Han Jung, Chan Kwon Jung, Ahwon Lee, Gyeongsin Park, Jinyoung Yoo, Kyo Young Lee
Korean J Pathol. 2007;41(2):95-102.
  • 1,561 View
  • 15 Download
AbstractAbstract PDF
BACKGROUND
The catalytic subunit of telomerase, hTERT (telomerase reverse transcriptase), is one of the most important components of telomerase, and performs a pivotal role in the mechanism underlying the regulation of telomerase activity in cellular immortalization and carcinogenesis. The principal objective of this study was to investigate hTERT expression in patients with non-small cell lung carcinomas (NSCLCs), and to evaluate its clinical significance and association with the expression of p16 and p53.
METHODS
Using tissue microarray, the protein expression profiles of hTERT, p16 and p53 were investigated via immunohistochemistry in 167 samples of NSCLCs.
RESULTS
Expression was observed in 54.5% (91/167) of the tumors, which were predominantly squamous cell carcinomas. Patients evidencing hTERT expression in their tumors exhibited significantly poorer survival rates than did patients without hTERT expression in early-stage NSCLCs (p=0.0125). According to the results of our Cox regression analysis, hTERT expression proved to be an independent prognostic factor (p=0.006), particularly for squamous cell carcinomas (p=0.019). hTERT expression was not correlated with p16 expression, but was rather associated with the expression of p53 (p=0.002).
CONCLUSIONS
Our results show that hTERT may perform a function in the progression of NSCLC, and that its detection may be useful in predicting the prognosis of NSCLC patients in the early stages of the disease, as well as in the development of a targeted therapy in these tumors.

JPTM : Journal of Pathology and Translational Medicine